ImmunoGen, Inc. Press Releases

Get IMGN Alerts
*Delayed - data as of Oct. 23, 2014 11:53 ET  -  Find a broker to begin trading IMGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    IMGN Real Time
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Filtered By
Ordered By
Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered by Subcutaneous Route to Prostate Cancer Patients
10/10/2014 11:30:00 AM - Business Wire

ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2015 Financial Results
10/10/2014 11:30:00 AM - Business Wire
▲1.76 % Price Change since this news event. The Volume Ratio is 0.93.This reflects the trading volume for the event day.  Source:
Volume ratio on event day

ImmunoGen, Inc. Hires Sandra E. Poole as Senior Vice President of Technical Operations
9/15/2014 8:30:00 AM - Business Wire

ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
9/2/2014 4:15:00 PM - Business Wire

ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
8/4/2014 2:45:00 PM - Business Wire

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
8/1/2014 6:30:00 AM - Business Wire